AI
| Followers | 55 |
| Posts | 1664 |
| Boards Moderated | 0 |
| Alias Born | 12/11/2012 |
Wednesday, November 12, 2014 6:58:24 PM
TLOG-$3.99 some DD and Insider purchase reported today.
Reported today 11/12/2014: Paul J. Schmitt Acquires 20,000 Shares of Tetralogic Pharmaceuticals Corp Stock (TLOG)
"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Director Paul J. Schmitt acquired 20,000 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $4.10 per share, with a total value of $82,000.00. "
Read more here; http://www.wkrb13.com/markets/422710/insider-buying-paul-j-schmitt-acquires-20000-shares-of-tetralogic-pharmaceuticals-corp-stock-tlog/
Pipeline:
ONCOLOGY PRE-CLINICAL PHASE 1 PHASE 2
Myelodysplastic Syndromes (MDS) Birinapant
Cutaneous T-Cell Lymphoma (CTCL) SHAPE
Colorectal Cancer (CRC) Birinapant
Ovarian Cancer Birinapant
INFECTIOUS DISEASE
Hepatitis B Birinapant
More here: http://tetralogicpharma.com/clinical-trials/
Market Cap (yahoo): $88.59M
Cash as of Sept 30,2014 = $65.1 M
"Cash, cash equivalents, and marketable securities totaled $65.1 million at September 30, 2014, as compared to $55.1 million at December 31, 2013. "
Catalysts:
*** Birinapant/conatumumab Program: Enrollment continues in a signal-seeking study in combination with conatumumab, Amgen's TRAIL agonist antibody, in 3rd line ovarian cancer. We currently expect data around the end of 2014.
****Birinapant HBV Program:We are commencing enrollment in a multiple ascending dose study of birinapant in subjects with chronic hepatitis B in the fourth quarter of 2014. We currently expect data to be generated around the middle of 2015.
Birinapant MDS Program: "We currently expect interim data from the Phase 2 study in the middle of 2015."
SHAPE CTCL Program: "We are advancing SHAPE into a randomized Phase 2 clinical trial in early stage CTCL. We currently expect data around the end of 2015.
Share structure:
"Shares issued and outstanding as of September 30, 2014 were 22.3 million, not including outstanding stock options to purchase 3.2 million shares and 7.0 million shares underlying the company's outstanding convertible notes."
chart looks like it has bottomed out:
http://finviz.com/quote.ashx?t=TLOG
Reported today 11/12/2014: Paul J. Schmitt Acquires 20,000 Shares of Tetralogic Pharmaceuticals Corp Stock (TLOG)
"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Director Paul J. Schmitt acquired 20,000 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $4.10 per share, with a total value of $82,000.00. "
Read more here; http://www.wkrb13.com/markets/422710/insider-buying-paul-j-schmitt-acquires-20000-shares-of-tetralogic-pharmaceuticals-corp-stock-tlog/
Pipeline:
ONCOLOGY PRE-CLINICAL PHASE 1 PHASE 2
Myelodysplastic Syndromes (MDS) Birinapant
Cutaneous T-Cell Lymphoma (CTCL) SHAPE
Colorectal Cancer (CRC) Birinapant
Ovarian Cancer Birinapant
INFECTIOUS DISEASE
Hepatitis B Birinapant
More here: http://tetralogicpharma.com/clinical-trials/
Market Cap (yahoo): $88.59M
Cash as of Sept 30,2014 = $65.1 M
"Cash, cash equivalents, and marketable securities totaled $65.1 million at September 30, 2014, as compared to $55.1 million at December 31, 2013. "
Catalysts:
*** Birinapant/conatumumab Program: Enrollment continues in a signal-seeking study in combination with conatumumab, Amgen's TRAIL agonist antibody, in 3rd line ovarian cancer. We currently expect data around the end of 2014.
****Birinapant HBV Program:We are commencing enrollment in a multiple ascending dose study of birinapant in subjects with chronic hepatitis B in the fourth quarter of 2014. We currently expect data to be generated around the middle of 2015.
Birinapant MDS Program: "We currently expect interim data from the Phase 2 study in the middle of 2015."
SHAPE CTCL Program: "We are advancing SHAPE into a randomized Phase 2 clinical trial in early stage CTCL. We currently expect data around the end of 2015.
Share structure:
"Shares issued and outstanding as of September 30, 2014 were 22.3 million, not including outstanding stock options to purchase 3.2 million shares and 7.0 million shares underlying the company's outstanding convertible notes."
chart looks like it has bottomed out:
http://finviz.com/quote.ashx?t=TLOG
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
